Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 15/20 | 0.76 |
| ▸ | FNTB | P49356 | 15/20 | 0.76 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.46 |
| ▸ | RORC | P51449 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6010278 | 0.88 | FNTA (0.90) | FNTAFNTBPGGT1BRORC | |
| SCHEMBL6169556 | 0.88 | FNTA (0.77) | FNTAFNTBPGGT1BRORC | |
| SCHEMBL7658457 | 0.87 | FNTA (0.84) | FNTAFNTBPGGT1BRORC | |
| SCHEMBL13529456 | 0.87 | FNTA (1.00) | FNTAFNTBPGGT1BRORC | |
| SCHEMBL6009961 | 0.86 | FNTA (0.76) | FNTAFNTBPGGT1B | |
| SCHEMBL6169332 | 0.85 | FNTA (0.84) | FNTAFNTBPGGT1BRORC | |
| SCHEMBL7815392 | 0.85 | FNTA (0.84) | FNTAFNTBPGGT1BRORC | |
| SCHEMBL6170013 | 0.85 | FNTA (0.82) | FNTAFNTBPGGT1BRORC | |
| SCHEMBL6169281 | 0.84 | FNTA (0.79) | FNTAFNTBPGGT1BRORC | |
| SCHEMBL5657968 | 0.84 | FNTA (0.87) | FNTAFNTBPGGT1BRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067531-B2 | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-27 | — | — | US | disclosed |
| US-20030199547-A1 | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives | JANSSEN-CILAG S.A. (FR) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199547-A1 | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives | FNTA, FNTB, RCE1 | FNTA 1/4885FNTB 2/4885CNR1 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.